On August 27, 2025 Oncoinvent reported continued progress in the ongoing Phase 2 trial in ovarian cancer with a strong focus on advancing the program and maximizing recruitment (Press release, Oncoinvent, AUG 27, 2025, View Source [SID1234655534]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Highlights for the first half of 2025:

Radspherin

Positive final data from Phase1/2a trial in colorectal cancer patients
Positive interim 18-months data from Phase1 trial in ovarian cancer patients
Positive read-out of safety lead-in cohort and opening of randomized part of Phase 2 trial in ovarian cancer patients
Regulatory approvals for additional sites for the randomized Phase 2 trial in ovarian cancer, with expected onboarding before end of 2025
Corporate

Operating expenses reduced by 28% versus last year
Merger with BerGenBio
Fully guaranteed rights issue of NOKm 130
CEO Øystein Soug and CFO Tore Kvam will present the results for the first half of 2025 at a webcast available at https://channel.royalcast.com/landingpage/hegnarmedia/20250827_3/, Wednesday 27 August at 08:00 CEST. The presentation and Q&A will be held in English. A recording of the webcast will be made available on our website shortly after the presentation.